Jump to:
James Gould joined Ropes & Gray's corporate department in the Boston office in 2023. James graduated from Boston University School of Law in 2023 after attending College of the Holy Cross as an undergraduate.
During law school, James served as an editor on Boston University’s Journal of Science and Technology Law. As an undergraduate James studied chemistry and was named a Goldwater Scholar in 2019 for his research on self-assembled monolayers.
Experience
- Advised Novo Nordisk in an asset purchase and license agreement with Omeros Corporation for Omeros’ drug candidate zaltenibart, a potential best-in-class treatment for rare blood and kidney disorders, in a deal worth up to $2.1 billion.
- Represented Accent Therapeutics in an asset purchase agreement with Boehringer Ingelheim for a preclinical potentially first-in-class small molecule oncology program for treating tumors with high interferon-stimulated gene expression.
- Represented Perceptive Xontogeny Venture Funds in a strategic partnership with Lexeo Therapeutics and venBio Partners to develop novel RNA-based therapeutics for genetic cardiac diseases through a new entity backed by up to $40 million in private equity financing from Perceptive and venBio.
- Advised Gilgamesh Pharmaceuticals in an agreement to sell its lead investigational candidate, bretisilocin, to AbbVie for up to $1.2 billion, inclusive of an upfront payment and development milestones. Bretisilocin is a potential best-in-class psychedelic compound for the treatment of patients with moderate to severe major depressive disorder.
- Advised Madrigal Pharmaceuticals in an exclusive global license agreement worth up to $2 billion with CSPC Pharmaceutical Group Limited for SYH2086, a preclinical oral small molecule GLP-1 receptor agonist.
- Represented a biopharmaceutical company in an AI-enabled research collaboration worth up to $5.3 billion with a China-based pharmaceutical group to advance the discovery and development of novel oral drug candidates across multiple disease indications.
- Represented Blackstone Life Sciences in its collaboration with Takeda where funds managed by Blackstone Life Sciences will provide up to $300 million to co-fund certain Phase 3 trials for mezagitamab.
- Represented a multinational pharmaceutical company in a strategic transaction with a Chinese biotechnology company to develop potential first-in-class peptide therapeutics worth up to $3.5 billion.
- Represented Sanofi in acquisition of Dren Bio’s bispecific antibody-based program in immunology deal worth up to $1.9 billion.
- Represented Amylyx Pharmaceuticals, a global pharmaceutical company focused on developing treatments for neurodegenerative diseases, in its successful bid of more than $35.1 million to purchase the avexitide assets of Eiger BioPharmaceuticals, Inc. in the sale of Eiger’s assets pursuant to Section 363 of the bankruptcy code.
- Represented Regeneron in acquisition of 2seventy Bio platforms to create new R&D unit Regeneron Cell Medicines.